Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129042 | 0.98 | LMNA (0.68) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL5076271 | 0.98 | LMNA (0.68) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL131133 | 0.93 | LMNA (0.61) | LMNAMAPTMAPK1ALDH1A1GAA | |
| Formaldehyde SCHEMBL5172703 | 0.89 | LMNA (0.72) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL15391 | 0.89 | LMNA (0.78) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL8104259 | 0.89 | LMNA (0.78) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL12132118 | 0.86 | LMNA (0.83) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL10788600 | 0.86 | LMNA (0.83) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL495594 | 0.86 | LMNA (0.83) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL494127 | 0.86 | LMNA (0.83) | LMNAMAPTMAPK1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-19 | — | — | US | disclosed |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20190117666-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| EP-2854815-B1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMA CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20170239265-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-9708292-B2 | Cyanopyrimidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20170196877-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9669075-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-06-06 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4760064-A | Cardiotonic agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-07-26 | — | — | US | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| EP-0187322-A1 | Carbostyril compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-16 | — | — | EP | disclosed |
| EP-0097280-B1 | AZOLYL-SUBSTITUTED OXIMINO-CYANO-ACETAMIDE DERIVATIVES | BAYER AG (DE) | 1985-08-28 | — | — | EP | disclosed |
| US-4518605-A | Fungicidal azole-substituted oximino-cyano-acetamide derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1985-05-21 | — | — | US | disclosed |
| US-4478848-A | Combating fungi with substituted anilinomethylene-oximes | BAYER AKTIENGESELLSCHAFT (DE) | 1984-10-23 | — | — | US | disclosed |
| EP-0097280-A2 | Azolyl-substituted oximino-cyano-acetamide derivatives | BAYER AG (DE) | 1984-01-04 | — | — | EP | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
| EP-0072970-A1 | Substituted anilinomethylene oximes, method for their preparation and their use as herbicides | BAYER AG (DE) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | LMNA 2122/4885MAPT 4608/4885MAPK1 3706/4885 |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | LMNA 2122/4885MAPT 4608/4885MAPK1 3706/4885 |
| US-20190117666-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | LMNA 2122/4885MAPT 4608/4885MAPK1 3706/4885 |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | LMNA 2122/4885MAPT 4608/4885MAPK1 3706/4885 |
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | LMNA 2122/4885MAPT 4608/4885MAPK1 3706/4885 |
| US-20170239265-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | LMNA 2122/4885MAPT 4608/4885MAPK1 3706/4885 |
| US-20170196877-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | LMNA 2122/4885MAPT 4608/4885MAPK1 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.